Top

Lung

Published in:

01-04-2020 | Lung Cancer | LUNG CANCER

High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1

Authors: Bing Hu, Xin Li, Ling Chen, Zhongliang Liu

Published in: Lung | Issue 2/2020

Objective

To explore the role of CARM1 in lung cancer (LC) and its relationship with TP53 and CTNNB1.

Methods

Lung cells H1299 and PC14 were randomly divided into six groups: ov-H1299, si-H1299, ov-PC14, si-PC14, Con-H1299, and Con-PC14. Transwell assay, plate clone formation assay, and flow cytometry were used to determine the migration, clone formation capacity, and apoptosis situation of LC cells in the six groups, respectively. Western blot assay was used to determine the protein expression of CARM1, TP53, and CTNNB1 in the six groups. CHIP assay was applied to analyze the combined characteristics of JUN and TP53 promoter. Co-immunoprecipitation was used to analyze the interaction between TP53 and CARM1/CTNNB1. Cox proportional hazard regression model was used to analyze the relevance between the expression of CARM1 and clinicopathological information of the patient. Kaplan−Meier plot was used to determine the relevance between CARM1 and patient survival.

Results

High expression of CARM1 inhibits the migration and proliferation of LC cells and promoted the apoptosis of LC cell. Overexpression of CARM1 promotes the expression of CARM1 and TP53, while decreases CTNNB1 expression. CARM1 supplementation of H1299 cells induced JUN aggregation on the TP53 promoter. TP53 and CARM1 protein/TP53 and CTNNB1 protein in H1299 cells were immunoprecipitated together. High expression of CARM1was negatively correlated with the degree of tumor metastasis. The survival period of patients with high expression CARM1 was greater than that of low expression.

Conclusion

Overexpression of CARM1 may inhibit the progression of LC by targeting TP53 via regulation CTNNB1.

Siegel RL, Miller KD, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65:5–29. https://doi.org/10.3322/caac.21254 CrossRefPubMed

Miranda TB, Miranda M, Frankel A, Clarke S (2004) PRMT7 Is a member of the protein arginine methyltransferase family with a distinct substrate specificity. J Biol Chem 279:22902–22907. https://doi.org/10.1074/jbc.M312904200 CrossRefPubMed

Elakoum R, Gauchotte G, Oussalah A et al (2014) CARM1 and PRMT1 are dysregulated in lung cancer without hierarchical features. Biochimie 97:210–218. https://doi.org/10.1016/j.biochi.2013.10.021 CrossRefPubMed

An W, Kim J, Roeder RG (2004) Ordered cooperative functions of PRMT1, p300, and CARM1 in transcriptional activation by p53. Cell 117:735–748. https://doi.org/10.1016/j.cell.2004.05.009 CrossRefPubMed

Cheng H, Qin Y, Fan H et al (2013) Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes. Diagn Pathol 8:129. https://doi.org/10.1186/1746-1596-8-129 CrossRefPubMedPubMedCentral

Li P, Yao H, Zhang Z et al (2008) Regulation of p53 target gene expression by peptidylarginine deiminase 4. Mol Cell Biol 28:4745–4758. https://doi.org/10.1128/MCB.01747-07 CrossRefPubMedPubMedCentral

Green DR, Kroemer G (2009) Cytoplasmic functions of the tumour suppressor p53. Nature 458:1127–1130. https://doi.org/10.1038/nature07986 CrossRefPubMedPubMedCentral

Pfister NT, Prives C (2016) Chromatin dysregulation by mutant p53. Oncotarget 7:29875–29876. https://doi.org/10.18632/oncotarget.7922 CrossRefPubMedPubMedCentral

Bulzico D, Torres DC, Ferreira GM et al (2017) A novel TP53 mutation associated with TWIST1 and SIP1 expression in an aggressive adrenocortical carcinoma. Endocr Pathol 28:326–331. https://doi.org/10.1007/s12022-017-9482-7 CrossRefPubMed

10.

Cho S-Y, Park C, Na D et al (2017) High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients. Exp Mol Med 49:e317. https://doi.org/10.1038/emm.2017.9 CrossRefPubMedPubMedCentral

11.

Saccani S, Natoli G (2002) Dynamic changes in histone H3 Lys 9 methylation occurring at tightly regulated inducible inflammatory genes. Genes Dev 16:2219–2224. https://doi.org/10.1101/gad.232502 CrossRefPubMedPubMedCentral

12.

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61:69–90. https://doi.org/10.3322/caac.20107 CrossRefPubMed

13.

Marchevsky AM, Gal AA, Shah S, Koss MN (2001) Morphometry confirms the presence of considerable nuclear size overlap between “small cells” and “large cells” in high-grade pulmonary neuroendocrine neoplasms. Am J Clin Pathol 116:466–472. https://doi.org/10.1309/H40B-8W14-4Q47-03EP CrossRefPubMed

14.

Fassina A, Cappellesso R, Fassan M (2011) Classification of non-small cell lung carcinoma in transthoracic needle specimens using microRNA expression profiling. Chest 140:1305–1311. https://doi.org/10.1378/chest.11-0708 CrossRefPubMed

15.

Chen D, Ma H, Hong H et al (1999) Regulation of transcription by a protein methyltransferase. Science 284:2174–2177. https://doi.org/10.1126/science.284.5423.2174 CrossRefPubMed

16.

Lee Y-H, Koh SS, Zhang X et al (2002) Synergy among nuclear receptor coactivators: selective requirement for protein methyltransferase and acetyltransferase activities. Mol Cell Biol 22:3621–3632. https://doi.org/10.1128/MCB.22.11.3621-3632.2002 CrossRefPubMedPubMedCentral

17.

Messaoudi SE, Fabbrizio E, Rodriguez C et al (2006) Coactivator-associated arginine methyltransferase 1 (CARM1) is a positive regulator of the Cyclin E1 gene. PNAS 103:13351–13356. https://doi.org/10.1073/pnas.0605692103 CrossRefPubMed

18.

Petitjean A, Achatz MIW, Borresen-Dale AL et al (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157–2165. https://doi.org/10.1038/sj.onc.1210302 CrossRefPubMed

19.

Shishkova E, Zeng H, Liu F et al (2017) Global mapping of CARM1 substrates defines enzyme specificity and substrate recognition. Nat Commun 8:15571. https://doi.org/10.1038/ncomms15571 CrossRefPubMedPubMedCentral

Title: High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1
Authors: Bing Hu
Xin Li
Ling Chen
Zhongliang Liu
Publication date: 01-04-2020
Publisher: Springer US
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Published in: Lung / Issue 2/2020
Print ISSN: 0341-2040
Electronic ISSN: 1432-1750
DOI: https://doi.org/10.1007/s00408-020-00324-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

High Expression of CARM1 Inhibits Lung Cancer Progression by Targeting TP53 by Regulating CTNNB1

Objective

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

High Systemic Immune-Inflammation Index (SII) Represents an Unfavorable Prognostic Factor for Small Cell Lung Cancer Treated with Etoposide and Platinum-Based Chemotherapy

Association of Serum TGF-β1 Levels with Different Clinical Phenotypes of Cystic Fibrosis Exacerbation

Peak Cough Flow in Children with Neuromuscular Disorders

Obstructive Sleep Apnea Severity and the Risk of Occupational Injury: A Prospective Observational Cohort

Is Metrnl an Adipokine İnvolved in the Anti-inflammatory Response to Acute Exacerbations of COPD?

Culturally Appropriate Outreach Specialist Respiratory Medical Care Improves the Lung Function of Children in Regional and Remote Queensland

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page